Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Francesco Schettini(Target (United States)), Navid Sobhani(University of Trieste), Anna Ianza(University of Trieste), Maria Chiara Lazzari(Istituti Ospitalieri di Cremona), Ottavia Bernocchi(University of Trieste), Fabiola Giudici(University of Padua), Marianna Sirico(Istituti Ospitalieri di Cremona), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Carla Strina(Istituti Ospitalieri di Cremona), Silvia Paola Corona(Hôpital Cardiologique du Haut-Lévêque), Eva Ciruelos(Hospital Universitario 12 De Octubre), Tiziana Triulzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Stephen B. Fox(Peter MacCallum Cancer Centre), Sherine Loi(The University of Melbourne), Manuela Milani(Humanitas University), Alfredo Molteni(Istituti Ospitalieri di Cremona), Maria Rosaria Cappelletti(Istituti Ospitalieri di Cremona)
Cited by 20
Related Papers
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k